https://orcid.org/0000-0002-2241-0954
References
- Yang E, Frazee BW. Infective endocarditis. Emerg Med Clin North Am. 2018;36:645–663. doi:10.1016/j.emc.2018.06.002
- Habib G, Lancellotti P, Antunes MJ, et al; ESC Scientific Document Group. 2015 ESC guidelines for the management of infective endocarditis: the task force for the management of infective endocarditis of the European Society of Cardiology (ESC). Endorsed by: European Association for Cardio-Thoracic Surgery (EACTS), the European Association of Nuclear Medicine (EANM). Eur Heart J. 2015;36(44):3075–3128. doi:10.1093/eurheartj/ehv319
- Falagas ME, Manta KG, Ntziora F, Vardakas KZ. Linezolid for the treatment of patients with endocarditis: a systematic review of the published evidence. J Antimicrob Chemother. 2006;58:273–280. doi:10.1093/jac/dkl219
- Colli A, Campodonico R, Gherli T. Early switch from vancomycin to oral linezolid for treatment of gram-positive heart valve endocarditis. Ann Thorac Surg. 2007;84:87–91. doi:10.1016/j.athoracsur
- Gordeev MF, Yuan ZY. New potent antibacterial oxazolidinone (MRX-I) with an improved class safety profile. J Med Chem. 2014;57(11):4487–4497. doi:10.1021/jm401931e
- Linezolid Tablets Prescribing Information. Available from: https://www.drugs.com/pro/linezolid-tablets.html. Accessed August 10, 2022.
- Wang W, Voss KM, Liu J, Gordeev MF. Nonclinical evaluation of antibacterial oxazolidinones contezolid and contezolid acefosamil with low serotonergic neurotoxicity. Chem Res Toxicol. 2021;34(5):1348–1354. doi:10.1021/acs.chemrestox.0c00524
- Chen X, Liu Y, Yu H, et al. Clinical characteristics, pathogenic distribution, treatment and prognosis of 300 patients with infective endocarditis hospitalized in fuwai hospital [In Chinese]. Chin Circ J. 2018;33:1102–1107.
- Cheng J, Hu H, Zhang H, et al. Pathogen distribution and clinical characteristics analysis of 802 patients with infective endocarditis [In Chinese]. Chin Circ J. 2020;35:180–184.
- Iversen K, Ihlemann N, Gill SU, et al. Partial oral versus intravenous antibiotic treatment of endocarditis. N Engl J Med. 2019;380:415–424. doi:10.1056/NEJMoa1808312
- Kawasuji H, Nagaoka K, Tsuji Y, et al. Effectiveness and safety of linezolid versus vancomycin, teicoplanin, or daptomycin against methicillin-resistant Staphylococcus aureus bacteremia: a systematic review and meta-analysis. Antibiotics. 2023;12(4):697. doi:10.3390/antibiotics12040697
- Carvalhaes CG, Duncan LR, Wang W, Sader HS. In vitro activity and potency of the novel oxazolidinone contezolid (MRX-I) tested against gram-positive clinical isolates from the United States and Europe. Antimicrob Agents Chemother. 2020;64(11):e01195–e01220. doi:10.1128/AAC.01195-20
- Ma GH, Li XY, Li MJ, Zhu HL. A case report of MRSA-associated sepsis successfully treated with contezolid in an elderly patient [in Chinese]. Chin J Pract Intern Med. 2022;42(12):1045–1047.